Virtual Library
Start Your Search
Marina Kelner Silveira
Author of
-
+
P10 - Health Services Research/Health Economics - Health Economics (ID 122)
- Event: WCLC 2020
- Type: Posters
- Track: Health Services Research/Health Economics
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P10.02 - A comparison Between the Cost of Lung Cancer Treatment and how much is made Available by Brazilian Government (ID 3102)
00:00 - 00:00 | Presenting Author(s): Marina Kelner Silveira
- Abstract
Introduction
Worldwide, lung cancer is the leading cause of cancer death. Most patients are diagnosed in stage IV and are treated with palliative intent. In this scenario, molecular target therapy and immunotherapy increased the survival of these patients. However, in Brazil, access to these therapies is very different in relation to the public and private health system. In this study, we compared the cost of the best treatment available to patients in the private system with the amount paid by the Brazilian government to treat these patients in the public health system
Methods
Lung cancer was classified into 10 subtypes according to histology, molecular profile and PDL1 expression. A panel of experts defined the best treatment sequence for each of the subtypes. The treatment duration considered for each palliative line was the median progression-free survival(mPFS) observed in the main studies. The calculation of the cost of each treatment line was based on the CMED value plus taxes. The treatment cost for each subtype was obtained by adding the costs of each treatment line. The final fictitious value of the best treatment for lung cancer available in Brazil was obtained adding the proportional cost of each subtype. The amount paid by government to treat these patients was calculated by multiplying the number of months corresponding to the mPFS by the value of the APAC and then for the proportional frequency of the subtype.
Results
An impressive difference was observed. The fictitious value paid by government for treating lung cancer in Brazil is R$8.000,00 and the fictitious cost of the best treatment is R$729.454,00, which represents a difference of 9.118%.
Conclusion
The cost of the best treatment for lung cancer in Brazil is much higher than the value available in the public health system. This deprivation of access may be jeopardizing the survival of these Brazilians.
